$360 Billion Women's Health Market Accelerates as FDA Eases Hormone Therapy Warnings
Updated
Updated · Bloomberg · Jul 12
$360 Billion Women's Health Market Accelerates as FDA Eases Hormone Therapy Warnings
1 articles · Updated · Bloomberg · Jul 12
Summary
$360 billion in women's health spending is being reshaped as menopause care draws fresh attention from drugmakers, startups, employers and investors after years of neglect.
FDA rollback of long-standing hormone replacement therapy warnings has helped speed that shift, easing a major barrier around a condition affecting roughly half the population.
Naomi Watts, startups including Stripes and Midi Health, and investors such as Amboy Street Ventures are turning midlife women's health into a fast-growing commercial category.
The expansion is also creating a new sorting problem for patients, who must distinguish evidence-based treatment from wellness products and marketing hype.
As menopause care becomes a billion-dollar industry, who profits most: patients or corporate investors?
Is the booming menopause market a true healthcare revolution or just a celebrity-fueled investment bubble?
With countless new menopause products, how can women find proven medical care amid the marketing hype?
2025 FDA Overhaul of HRT Warnings: Expanded Access, Market Growth, and Global Impact on Menopause Treatment
Overview
In November 2025, the FDA announced it would remove broad 'black box' warnings from most hormone replacement therapy (HRT) products, reflecting an evolving understanding of HRT and growing public awareness. Historically, these severe warnings deterred many postmenopausal women from using HRT due to fear, even though HRT can offer significant long-term health benefits. The FDA’s decision aims to provide women with more nuanced and comprehensive information, moving away from blanket cautions and encouraging informed discussions between patients and healthcare providers. This marks a pivotal shift in how HRT risks and benefits are communicated and understood.